Is Affymax Inc halal to invest in?

According to Musaffa's Shariah screening methodology, Affymax Inc (AFFY) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company's business activities and financial ratios to determine whether it meets Islamic investment guidelines.

Is Affymax Inc a Shariah-compliant stock?

A stock is Shariah-compliant if the company operates in permissible business activities and meets Islamic financial screening thresholds. Musaffa analyzes Affymax Inc using these criteria to determine its compliance status.

Can Muslims buy shares of Affymax Inc?

Muslim investors may consider investing in Affymax Inc if it meets Shariah compliance standards. Investors typically review the company's business activities, debt levels, and non-permissible income before making a decision.

Why is Affymax Inc classified as NOT COVERED?

Musaffa determines the Shariah status of Affymax Inc by analyzing whether the company's core business operations are permissible and whether its financial ratios fall within accepted Islamic thresholds.

How often is the Shariah compliance for Affymax Inc updated?

The Shariah compliance status of Affymax Inc may be updated periodically when new financial statements, earnings reports, or business activity information become available.

Can a halal stock like Affymax Inc become non-compliant?

Yes. A stock that is currently Shariah-compliant may become non-compliant if the company's financial ratios exceed Shariah thresholds or its business activities change.

Where can I check the Shariah status of Affymax Inc?

You can check the latest Shariah compliance status of Affymax Inc on Musaffa's stock page, where screening results and key financial indicators are updated to help Muslim investors make informed decisions.

Affymax Inc. Stock Analysis AFFY

United States N/A Nano Cap

Affymax, Inc. is a biopharmaceutical company. The company is headquartered in New York City, New York and currently employs 4 full-time employees. The company went IPO on 2006-12-15. The Company’s product OMONTYS (peginesatide) is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent (ESA), designed to stimulate production of red blood cells. The firm has a collaboration to develop and commercialize peginesatide with Takeda Pharmaceutical Company Limited. In March 2012, the Food and Drug Administration (FDA) approved the Company’s product, OMONTYS.

Key Statistics of Affymax Inc (AFFY)

Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.

Today's Range

$0.00$0.00

Today's Open

$0.00

Volume

9500.00

P/E Ratio (TTM)

52 Week Range

$0.00$0.00

Market Cap

41.24K

Avg. Volume

5016.70

Dividend Yield

Financial Metrics & Statements of Affymax Inc (AFFY)

FAQ's for Affymax Inc (AFFY)

According to Musaffa’s Shariah screening methodology, Affymax Inc (AFFY) is currently classified as NOT COVERED as of May 2026. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.